Aptazapine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Aptazapine
Accession Number
DB09305
Type
Small Molecule
Groups
Experimental
Description

Aptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity. It antagonised α2 adrenergic receptors approximately 10 times more effectively than mianserin, antagonised 5-HT2 receptors, agonised H1 receptors, and did not affect reuptake of serotonin or norepinephrine. Although Aptazapine reached clinical trials, it was never marketed.

Structure
Thumb
Synonyms
Not Available
External IDs
CGS 7525A / CGS-7525A
Product Ingredients
IngredientUNIICASInChI Key
Aptazapine maleate7X768418RT71576-41-5JJTOHZLQMBVMPF-BTJKTKAUSA-N
Categories
UNII
240J927J1R
CAS number
71576-40-4
Weight
Average: 253.349
Monoisotopic: 253.157897624
Chemical Formula
C16H19N3
InChI Key
MNHDDERDSNZCCK-UHFFFAOYSA-N
InChI
InChI=1S/C16H19N3/c1-17-9-10-19-14-6-3-2-5-13(14)11-18-8-4-7-15(18)16(19)12-17/h2-8,16H,9-12H2,1H3
IUPAC Name
17-methyl-6,14,17-triazatetracyclo[12.4.0.0²,⁶.0⁸,¹³]octadeca-2,4,8(13),9,11-pentaene
SMILES
CN1CCN2C(C1)C1=CC=CN1CC1=C2C=CC=C1

Pharmacology

Indication

Investigated for the treatment of depression.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Aptazapine.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Aptazapine.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Aptazapine.
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Aptazapine.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Aptazapine.
ClorgilineThe risk or severity of adverse effects can be increased when Clorgiline is combined with Aptazapine.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Aptazapine.
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Aptazapine.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Aptazapine.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Aptazapine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Gower AJ, Broekkamp CL, Rijk HW, Van Delft AM: Pharmacological evaluation of in vivo tests for alpha 2-adrenoceptor blockade in the central nervous system and the effects of the enantiomers of mianserin and its aza-analog ORG 3770. Arch Int Pharmacodyn Ther. 1988 Jan-Feb;291:185-201. [PubMed:2896489]
  2. Liebman JM, Lovell RA, Braunwalder A, Stone G, Bernard P, Barbaz B, Welch J, Kim HS, Wasley JW, Robson RD: CGS 7525A, a new, centrally active alpha 2 adrenoceptor antagonist. Life Sci. 1983 Jan 24;32(4):355-63. [PubMed:6131367]
External Links
PubChem Compound
51355
PubChem Substance
310265194
ChemSpider
46513
ChEMBL
CHEMBL336712
Wikipedia
Aptazapine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.7 mg/mLALOGPS
logP2.48ALOGPS
logP2.69ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)6.92ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area11.41 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity78.91 m3·mol-1ChemAxon
Polarizability29.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Dialkylarylamines / N-methylpiperazines / Aralkylamines / Benzenoids / Pyrroles / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
1,4-benzodiazepine / Tertiary aliphatic/aromatic amine / Dialkylarylamine / N-methylpiperazine / N-alkylpiperazine / Aralkylamine / 1,4-diazinane / Piperazine / Benzenoid / Pyrrole
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on November 12, 2015 09:14 / Updated on March 01, 2020 23:40

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates